Latest Underwriting Agreement News

AnteoTech has secured independent validation for its Ultranode™ 95 silicon anode in commercial drone battery cells, launched a new battery additive, and strengthened its cash position with a A$10 million capital raise.

Starpharma launches a fully underwritten $32 million entitlement offer to fund the Phase 1 trial of its DEP® HER2-Lutetium radiopharmaceutical and accelerate its targeted oncology asset development.

Titanium Sands Limited (ASX:TSL) has launched a fully underwritten offer of up to 242.7 million New Options to holders of its expired TSLOA Options, aiming to raise approximately $243,000 before expenses. The offer includes a substantial bonus component and options allocated to CPS Capital as fees for managing a $1.2 million loan.

Alara Resources (ASX:AUQ) is seeking to raise $3.84 million through a pro-rata non-renounceable entitlement offer, partially underwritten by major shareholder ATI. The funds will primarily support exploration and working capital amid ongoing operational progress at its Oman copper projects.

American Tungsten & Antimony Ltd has inked an underwriting deal with GBA Capital to ensure full subscription of up to 69 million AT4N options expiring this month, securing potential capital injection amid its US critical minerals push.

Sprintex Limited has locked in underwriting agreements covering 8.7 million unexercised options, potentially raising up to A$870,000. The company also agreed to extend a A$1.85 million convertible note maturity by one year, pending shareholder approval.

Strategic Energy Resources (ASX:SER) has raised $1.5 million through a discounted share placement and a fully underwritten share purchase plan to back a high-impact drilling campaign at its Diamantina Copper-Gold Project in Queensland.

VRX Silica Limited has successfully closed a renounceable rights issue, securing $2.86 million to fund key developments at its Arrowsmith North and Muchea silica sand projects.

National Australia Bank updates its interim dividend framework, setting DRP and BSP prices with a partial underwriting by Goldman Sachs for up to AUD 1 billion.

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Silver Mines has locked in a $7.56 million capital raise by entering an underwriting agreement with Petra Capital to cover the exercise of nearly 63.2 million unlisted options expiring mid-June.

Tivan Limited has locked in a minimum $15 million funding package through a $10 million option underwriting agreement and a $5 million share placement with strategic investor ETFS Capital, supporting accelerated development across its Australian and Timor-Leste projects.